Loss of RanBP9 cooperates with p53 deficiency to promote sarcomagenesis.

Brianna C Gonga-Cavé, Gabriel Onea, Xu Wang, Sean P Cregan, Michael B Boffa, Patti K Kiser, Caroline Schild-Poulter

Abstract read

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Brianna C Gonga-CavéRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Gabriel OneaRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Xu WangRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Sean P CreganNeuroscience Program, Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.

Michael B BoffaRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Patti K KiserDepartment of Pathology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.

Caroline Schild-PoulterRobarts Research Institute, University of Western Ontario, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Ubiquitination is a major regulatory process that is often dysregulated in carcinogenesis. The C-terminal to LisH (CTLH) complex is a multi-subunit E3 ubiquitin ligase that has been shown to exert tumor-promoting and tumor-suppressing functions. Its core scaffolding subunit, RanBP9, has been implicated in regulating oncogenic signaling, but it remains unclear whether RanBP9 loss promotes tumorigenesis Objectives: This study aimed to evaluate the functional consequence of RanBP9 loss, alone or in combination with p53 deficiency, in mice. Methods: Mice with single or combined germline deletion of Results: Biallelic deletion of Discussion: Loss of RanBP9 induces deregulation of signaling cascades, and combined with p53 deficiency, further promotes sarcoma development in mice. This mouse model provides a valuable platform to further study pathways and candidates regulated by the CTLH complex in sarcoma biology.

Indexed as

CTLH complexE3 ubiquitin ligasep53RanBP9sarcomatumor suppressor proteins

Identifiers

PMID42755890

DOI10.3389/fonc.2026.1743582

PMCPMC13581892

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.